Hauck Aufhäuser Investment Banking Analysts Give Stratec (ETR:SBS) a €97.00 Price Target

Stratec (ETR:SBSGet Rating) received a €97.00 ($103.19) target price from Hauck Aufhäuser Investment Banking in a research note issued to investors on Friday, Borsen Zeitung reports. Hauck Aufhäuser Investment Banking’s price objective points to a potential upside of 43.07% from the stock’s previous close.

Other equities research analysts have also recently issued research reports about the company. Berenberg Bank set a €77.00 ($81.91) price objective on Stratec in a report on Friday. Deutsche Bank Aktiengesellschaft set a €119.00 ($126.60) price objective on shares of Stratec in a research report on Wednesday, February 15th.

Stratec Price Performance

Shares of ETR SBS opened at €67.80 ($72.13) on Friday. Stratec has a fifty-two week low of €72.70 ($77.34) and a fifty-two week high of €130.60 ($138.94). The company has a debt-to-equity ratio of 38.79, a current ratio of 3.48 and a quick ratio of 1.65. The stock has a market capitalization of $822.41 million, a price-to-earnings ratio of 29.74, a PEG ratio of 10.43 and a beta of 0.30. The business has a 50-day moving average of €82.80 and a 200-day moving average of €82.94.

About Stratec

(Get Rating)

Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It operates through three segments: Instrumentation, Diatron, and Smart Consumables. The Instrumentation segment designs and manufactures automated analyzer systems, including service parts and consumables for clinical diagnostics and biotechnology customers.

See Also

Receive News & Ratings for Stratec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stratec and related companies with MarketBeat.com's FREE daily email newsletter.